• GlobeImmune Inc., of Louisville, Colo., said it started a Phase I trial of GI-6301 , a Targmogen candidate, in patients with metastatic cancers containing brachyury protein, which is overexpressed in tumor types such as breast, colon, lung and prostate cancers.